Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 6,016 Cr.
- Current Price ₹ 1,051
- High / Low ₹ 1,176 / 421
- Stock P/E 50.8
- Book Value ₹ 156
- Dividend Yield 0.00 %
- ROCE 19.0 %
- ROE 17.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 36.5% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Allcap BSE Healthcare BSE SmallCap BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
356 | 373 | 411 | 801 | 926 | 1,081 | 1,178 | |
315 | 322 | 356 | 704 | 813 | 927 | 1,003 | |
Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 175 |
OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% |
0 | 1 | 1 | 3 | 9 | 12 | 12 | |
Interest | 6 | 5 | 4 | 6 | 20 | 21 | 8 |
Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 18 |
Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 161 |
Tax % | 20% | 26% | 26% | 25% | 26% | 27% | |
20 | 28 | 34 | 64 | 68 | 94 | 118 | |
EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 20.68 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 38% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 37% |
3 Years: | 40% |
TTM: | 53% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 23% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 |
Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 838 |
72 | 54 | 46 | 199 | 237 | 245 | 261 | |
68 | 81 | 179 | 167 | 191 | 240 | 278 | |
Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,435 |
78 | 73 | 79 | 183 | 183 | 358 | 361 | |
CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 452 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
144 | 172 | 283 | 392 | 500 | 617 | 621 | |
Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,435 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
19 | 31 | 42 | 59 | 67 | 146 | |
-9 | -6 | -20 | -188 | -91 | -499 | |
-9 | -23 | -19 | 125 | 27 | 361 | |
Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 93 | 85 | 123 | 97 | 104 | 97 |
Inventory Days | 50 | 84 | 107 | 76 | 77 | 91 |
Days Payable | 80 | 92 | 132 | 86 | 105 | 113 |
Cash Conversion Cycle | 64 | 77 | 99 | 87 | 77 | 75 |
Working Capital Days | 77 | 86 | 73 | 97 | 98 | 88 |
ROCE % | 26% | 28% | 31% | 24% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Dec - Scheduled analyst/investor meeting on December 5, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Nov - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Nov - Transcript of Q2 FY25 earnings call released.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - The officials of the Company will be attending the Investor Conference as per the below details: 1. 18th November, 2024 at 10:00 A.M - 02:00 …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Read with Schedule III (Part A) of SEBI (LODR), Regulations 2015, we would like to inform you that the officials of the Company will be …
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.